Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci

被引：26

作者：

Betriu, C ^{[1
]}

Redondo, M ^{[1
]}

Boloix, A ^{[1
]}

Gómez, M ^{[1
]}

Culebras, E ^{[1
]}

Picazo, JJ ^{[1
]}

机构：

[1] Hosp Clin Sao Carlos, Dept Clin Microbiol, Madrid 28040, Spain

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2001年 / 48卷 / 06期

关键词：

D O I：

10.1093/jac/48.6.911

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The activity of linezolid was determined against 225 recently isolated methicillin-resistant Staphylococcus aureus (MRSA) and 20 methicillin-resistant coagulase-negative staphylococci (CoNS) with decreased levels of susceptibility to teicoplanin. Linezolid activity was compared with other new agents (quinupristin-dalfopristin, trovafloxacin, moxifloxacin, levofloxacin and telithromycin) and six other antimicrobials (erythromycin, clindamycin, gentamicin, vancomycin, teicoplanin and rifampicin). The in vitro activity of linezolid was similar to that of vancomycin. Linezolid inhibited all MRSA strains at between 0.1 and 2 mg/L and all CoNS strains tested at between 0.2 and 0.5 mg/L. These results suggest that linezolid would be useful for the treatment of infections involving these organisms.

引用

页码：911 / 913

页数：3

共 10 条

[1] Glycopeptide resistance in coagulase-negative staphylococci [J].

Biavasco, F ;

Vignaroli, C ;

Varaldo, PE .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2000, 19 (06) :403-417

[2] Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections [J].

Chien, JW ;

Kucia, ML ;

Salata, RA .

CLINICAL INFECTIOUS DISEASES, 2000, 30 (01) :146-151

[3] Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin [J].

Hiramatsu, K ;

Aritaka, N ;

Hanaki, H ;

Kawasaki, S ;

Hosoda, Y ;

Hori, S ;

Fukuchi, Y ;

Kobayashi, I .

LANCET, 1997, 350 (9092) :1670-1673

[4] Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains [J].

Jones, ME ;

Visser, MR ;

Klootwijk, M ;

Heisig, P ;

Verhoef, J ;

Schmitz, FJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) :421-423

[5]

KLOOS WE, 1999, MANUAL CLIN MICROBIO, P271

[6] In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis [J].

Mulazimoglu, L ;

Drenning, SD ;

Yu, VL .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2428-2430

[7]

National Committee for Clinical Laboratory Standards, 1997, M7A4 NCCLS

[8] In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci [J].

Noskin, GA ;

Siddiqui, F ;

Stosor, V ;

Hacek, D ;

Peterson, LR .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) :2059-2062

[9] Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus [J].

Tenover, FC ;

Biddle, JW ;

Lancaster, MV .

EMERGING INFECTIOUS DISEASES, 2001, 7 (02) :327-332

[10] Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci [J].

von Eiff, C ;

Peters, G .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (04) :569-573

← 1 →